● TIER 3 — Information onlyGRADE B-Nootropic / neuro peptides
Semax (Семакс, Met-Glu-His-Phe-Pro-Gly-Pro)
Neuropeptides. Research verification: Yes (TGA pending). Origin: Russia (Institute of Molecular Genetics RAS; Peptogen). Citations verified: yes. 3 human study record(s) in the FitClinicMD studies database.
GOALS · Cognition
FDA status
Not approved.
Compounding (503A/503B)
Semax: Removed from 503A Category 2 on ~Apr 22 2026 after nominations were withdrawn; PCAC voted Jul 23-24 2026 to recommend 503A bulks-list inclusion, but no rulemaking yet, so not lawfully compoundable and not in Category 1. FDA list: Selank: nominated-but-withdrawn.
DEA
Not controlled.
WADA (sport)
Not listed on 2026 Prohibited List (no matching section found)
Mechanism
Tuftsin analog / ACTH(4-10) analog. (East) ACTH(4-7) analog with Pro-Gly-Pro; neurotrophic (BDNF) effects mainly in animal work; no corticotropic activity.
Human evidence · 3
Meta-analysis: efficacy of Semax in acute ischemic stroke.
meta-analysis
Effectiveness of semax in acute hemispheric ischemic stroke.
other/unspecifiedPMID 11517472 →
Efficacy of semax at different stages of ischemic stroke.
other/unspecifiedPMID 29798983 →
Reference only. This page summarizes publicly available regulatory and research information about Semax (Семакс, Met-Glu-His-Phe-Pro-Gly-Pro). It is not a prescription, an endorsement, or an offer to dispense, and regulatory status can change. Clinicians should verify current status before prescribing or compounding.